LEI:
549300Q7EXQQH6KF7Z84
14 October
2024
RTW Biotech Opportunities
Ltd
Monthly Valuation Update and
Factsheet
-2.8% NAV movement for the
month
RTW Biotech Opportunities Ltd (the "Company") announces that the unaudited
net asset value attributable to the ordinary shares of the Company
at the close of business on 30 September 2024 (the "NAV") was US$685.9 million, or US$1.95
per ordinary share, -2.8% from the previous month.
The monthly factsheet
is available on the Company's website:
https://www.rtwfunds.com/rtw-biotech-opportunities-ltd/factsheets-letters/
Highlights from the
Investment Manager's quarterly letter:
· Alongside our partners, we unveiled our first obesity NewCo,
Kailera Therapeutics. Kailera's most advanced program is an
injectable GLP-1 that has demonstrated excellent Phase 2 results
and includes an oral GLP in the clinic.
· September was the most active month for IPOs in our space
since 2022. Four IPOs were priced; all were upsized and trading up
post-market.
· Two of
our private companies had IPOs in the third quarter: BioAge Labs
and Artiva Biotherapeutics. Both have traded well since. So far
this year, the private portfolio has now seen five liquidity
events.
· Avidity Biosciences continued its climb this year on the back
of good data from its third program, AOC1044 for Duchenne
patients.
· Rocket
Pharmaceuticals slid due to investor frustration over slow
execution on the Danon trial, unfounded rumours of a clinical hold,
and a delayed submission for Fanconi.
· We
made two new private investments in the quarter. Jade Biosciences
is an exciting new biotech developing best-in-class therapies for
autoimmune diseases. We believe there is high potential and value
in Jade's pipeline, which aims to address significant unmet medical
needs in immunology and inflammation. Aktis Oncology is a
clinical-stage biotech company pioneering the discovery and
development of novel targeted alpha radiopharmaceuticals to treat a
range of solid tumours.
For
Further Information
|
RTW
Investments, LP
|
+44
20 7959 6361
|
|
Woody Stileman, Managing Director,
Business Development
Krisha McCune, Director, Investor
Relations
|
biotechopportunities@rtwfunds.com
|
|
Buchanan (PR & Communications Adviser)
|
+44
20 7466 5107
|
|
Charles Ryland
|
|
|
Henry Wilson
|
|
|
George Beale
|
|
|
|
|
|
Deutsche Numis (Joint Corporate Broker)
|
+44
20 7260 1000
|
|
Freddie Barnfield
|
|
|
Nathan Brown
|
|
|
Euan Brown
|
|
|
|
|
|
BofA Securities (Joint Corporate Broker)
|
+44
20 7628 1000
|
|
Edward Peel
|
|
|
Alex Penney
|
|
|
Cadarn Capital (Distribution & IR
Partner)
|
+44
73 6888 3211
|
|
David Harris
|
|
|
Elysium Fund Management Limited
Joanna Duquemin Nicolle, Chief
Executive Officer
Sadie Morrison, Managing
Director
|
+44
1481 703100
|
|
Morgan Stanley Fund Services USA LLC
|
+1
914 225 8885
|
About Biotech Opportunities Ltd:
RTW Biotech Opportunities Ltd (LSE:
RTW & RTWG) is an investment fund focused on identifying
transformative assets with high growth potential across the
biopharmaceutical and medical technology sectors. Driven by a
long-term approach to support innovative businesses, RTW Biotech
Opportunities Ltd invests in companies developing next-generation
therapies and technologies that can significantly improve patients'
lives. RTW Biotech Opportunities Ltd is managed by RTW Investments,
LP, a leading healthcare-focused
entrepreneurial investment firm with
deep scientific expertise and a strong track record of supporting
companies developing life-changing therapies.
Visit the website
at www.rtwfunds.com/rtw-biotech-opportunities-ltd for
more information.
***********
The information in this announcement
may include forward-looking statements, which are based on the
current expectations and projections about future events, and in
certain cases can be identified by the use of terms such as "may",
"will", "should", "expect", "anticipate", "project", "estimate",
"intend", "continue", "target", "believe" (or the negatives
thereon) or other variations thereon or comparable terminology.
These forward-looking statements, as well as those included in any
related materials, are subject to risks, uncertainties and
assumptions about the Company and/or its underlying investments,
including, among other things, the development of the applicable
entity's business, trends in its operating industry, expected use
of financing proceeds and future capital expenditures and
acquisitions. In light of these risks, uncertainties and
assumptions, the events in the forward-looking statements may not
occur.
The information contained in this
announcement is given at the date of its publication (unless
otherwise marked). No reliance may be placed for any purpose
whatsoever on the information or opinions contained in this
announcement or on its completeness, accuracy or
fairness.
***********